Navigation Links
MaxCyte to Present at the BIO CEO & Investor Conference
Date:2/6/2008

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical, non-viral cell loading systems, announces Douglas Doerfler, President & CEO, will be presenting at the BIO CEO & Investor Conference in New York, Waldorf=Astoria, on Monday, February 11, 2008 at 11:45AM.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product portfolio, partnering candidates, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provide safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
2. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
3. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
4. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
5. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
6. Vical to Present at BIO CEO and Investor Conference
7. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
8. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
9. DURECT to Present at BIO CEO Investor Conference 2008
10. BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
11. Bush Budget Represents Double Whammy Hit on U.S. Seniors Medicare-Financed Nursing Facility Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... A recent study by Harvard researchers suggests a link between ... people who received the vaccine were three-times more likely to ... who were not vaccinated. ,While this finding is disturbing, ... the development of MS was small -- 93 percent of ...
... caused by massive skin cancers on the face can be ... of the body. ,Most skin cancers arising on the ... family, and treatment is sought before the cancers get out ... cancers and repair the damage using flaps of skin located ...
... High levels of glycosylated hemoglobin, or HA1c, may be ... heart disease // and stroke, according to the new ... blood sugar control and the development of heart disease ... than 10,000 people, investigators found a 21-percent increase in ...
... friend might be able to detect bladder cancer . With ... malignant tumors in urine samples. ,Six dogs of ... discriminate between urine from patients with bladder cancer and that ... of urine from six control group participants and one bladder ...
... allergens and tobacco smoke could help reduce symptoms of ... than 900 children with asthma were studied. The children ... and lived in low-income areas. Previous research shows children ... at a disproportionately high rate. ,Researchers designed an ...
... even though evidence of its benefits is lacking in ... are no major benefits to surgically removing tonsils and ... examined 300 children, ages 2 to 8, with recurrent ... the children had the surgery, and half were allocated ...
Cached Medicine News:
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Multiplus no rub formula is the most ... All steps in one bottle without the ... your soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Grafton Trial Frame...
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Adult...
Medicine Products: